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Abstract
Purpose Our aim was to evaluate the
potential effect of imatinib mesylate (IM), a
small molecule that specifically inhibits the
tyrosine quinase receptors, on the
proliferation and invasive abilities of two
human retinoblastoma (Rb) cell lines.
Furthermore, the ability of IM to
radiosensitize Rb cells was evaluated. The
potential targets of IM (C-kit, PDGRF-a and
-b, and c-Abl) were also investigated in these
cell lines.
Methods Two human Rb cell lines (WERI-
RB-1 and Y79) were cultured under normal
growth conditions. An MTT-based
proliferation assay and a Matrigel invasion
assay were performed with and without
exposure to 10lM of IM. The cells were also
irradiated with graded dosages of 0, 2, 4, 6, 8,
and 10Gy with and without IM and their
proliferations rates were analyzed. Western
blot and immunocytochemical analysis of
cytospins were performed to evaluate the
expression of C-kit, PDGRF-a and -b, and
c-Abl.
Results When IM was added to both cell
lines a statistically significant (Po0.05)
reduction in proliferation and invasive
ability were observed. Exposure to IM also
significantly increased the radiosensitivity of
both Rb cell lines. The c-Abl expression was
strongly positive, PDGRF-a and -b expression
were also positive but the C-kit expression
was negative in both cell lines.
Conclusions These results indicate that
Gleevec may be useful as an adjuvant
treatment in Rb patients, specially those
considered for radiation therapy.
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Introduction
Retinoblastoma (Rb) is the most common
primary malignant intra-ocular tumor in
children and overall, the most common retinal
tumor. It represents approximately 4% of all
pediatric malignancies.1 Early diagnosis can
greatly improve both treatment efficacy and
survival rates, although some patients still
succumb because of metastatic disease. The
current therapies for Rb include intravenous
chemoreduction, thermotherapy, cryotherapy,
laser photocoagulation, plaque radiotherapy,
external beam radiotherapy, enucleation, orbital
exenteration, and systemic chemotherapy for
metastatic disease.1
Rb is generally a radiosensitive tumor. In the
treatment of Rb, radiation is delivered in the
form of brachytherapy (plaque radiotherapy) or
using an external beam (EBR) delivering
irradiation to the whole eye; the latter being
used only as a last choice of treatment before
enucleation in more advanced tumors. Earlier
stages of the disease expectedly respond better,
with success rates as high as 88%. When
irradiation is used as salvage therapy in stages
IV and V, half of the treated eyes still retain
useful vision.2 Unfortunately, the use of external
beam radiotherapy increases the incidence of
orbital hypoplasia, cataract, and second cancers
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in the field of irradiation, specially in patients younger
than 12 months of age.3 In the past 10 years, there has
been an effort by many centers to avoid EBR by the use of
chemotherapy to decrease the tumor dimensions
(chemoreduction). Focal treatment methods are then
used to consolidate the tumor control.4
Despite systemic chemotherapy with a variety of
chemotherapeutic agents, many tumors persist
unaffected.5,6 The presence of multiple side effects along
with the multidrug resistance often observed has
fostered the development of a new class of citotoxic
agents. These agents target individual genes that have
altered expression in tumors cells.7
Imatinib mesylate (IM, Gleevec, Novartis Pharma AG
Basel, Switzerland), formerly referred to as STI571, is a
therapeutic compound that specifically inhibits the
tyrosine kinase receptors: c-Abl, C-kit, and platelet-
derived growth factor (PDGF-a and -b) receptor. It is
known that protein tyrosine kinases (PTKs) have an
important role in cellular mechanisms, such as
differentiation, proliferation, and regulatory
mechanisms, as well as in signal transduction.8,9 The
expression of these targets and the use of IM as a new
therapeutic option have been studied in a wide variety of
human malignancies.9–12 Our group has already
demonstrated that the majority of Rb tumors express one
of the targets of IM: C-kit.13 The use of this drug is
already approved by the FDA for the treatment of
chronic myelogenous leukemia (CML) and
gastrointestinal tumors (GIST).8
The purpose of this study was to examine the potential
effect of Gleevec, on the proliferation and invasive
abilities of two human Rb cell lines, as well as the ability
to increase their radiosensitivity. To assess the expression
of the potential targets of Gleevec, we performed western
blot and immunocytochemistry on cytospin of both Rb
cell lines.
Materials and methods
Cell culture
The Rb cell lines were purchased from ATCC (Manassas,
VA, USA). Two non-adherent human Rb cell lines Y79
(ATCC catalog number HTB-18) and WERI-RB-1 (ATCC
catalog number HTB-169) were incubated at 37 1C in a
humidified 5% CO2-enriched atmosphere. The cells were
cultured in RPMI-1640 medium (Invitrogen, Burlington,
Ontario, Canada) supplemented with 10% heat-
inactivated fetal bovine serum, 1% fungizone, and 1%
penicillin–streptomycin purchased from Invitrogen. Cells
were cultured in 25 cm2 flasks (Fisher, Whitby, Ontario,
Canada) and observed twice weekly at every media
change for normal growth by phase contrast microscopy.
Cells were centrifuged at 120 g for 10 min to form a pellet,
and were then re-suspended in 1 ml of medium and
counted using the Trypan blue dye exclusion test.
In vitro proliferation assay
The MTT-based assay kit (TOX-1, Sigma-Aldrich,
St Louis, MO, USA) was performed in accordance
with the manufacturer’s recommendations. Briefly, the
two human Rb cell lines were seeded into wells at a
concentration of 10 000 cells per well, six wells per cell
line. A row of six wells exposed only to RPMI-1640
medium was used as a control. Twenty-four hours
following seeding, IM was added to the experimental
wells at a concentration of 10mM. The concentration of
IM was chosen based on the blood levels reported in
previous studies with the maximum tolerated dose of IM
on clinical trials.14 Cells were allowed to incubate for 48 h
following cell seeding. After this 48-h period, 10% MTT
was added to each well, then the cultures were
reincubated for a further 3 h. Once removed from the
incubator, the resulting formazan crystals were dissolved
using MTT Solubilization Solution (M-8910), and finally
cell number was determined spectrophotometrically by
subtracting absorbance at a wavelength of 690 nm from
the result at 570 nm. Each experiment was done in
triplicate.
In vitro invasion assay
A modified Boyden chamber consisting of a polyethelene
teraphthalate membrane (PET) with 8-mm diameter
pores, precoated with Matrigel, an artificial basement
membrane, (Beckton Dickenson Labware, Bedford, MA,
USA) was used as previously described,13 to assay for
invasive ability. PET membrane without Matrigel was
used as a control.
Briefly, 1.25 105 cells were added to the upper
chamber in RPMI-1640 medium with 0.1% FBS. RPMI-
1640 medium with 10% FBS was added to the lower
chamber as a chemoattractant to obtain the baseline
invasive ability of the cell lines. The effect of IM on
invasion was assayed by adding 10mM of IM to the
RPMI-1640 medium supplemented with 0.1% FBS in the
upper chamber. The chambers were then incubated at
37 1C in a 5% CO2- enriched atmosphere for 48 h to allow
for cellular invasion through the Matrigel.
Non-invading cells were removed from the upper
chamber by gently wiping the surface of the membrane
with a moist cotton swab. The membranes were then
stained using Diff-Quick staining set (Siemens Healthcare
Diagnostics, Tarrytown, NY, USA), which stains cell nuclei
purple and cytoplasm pink. Stained cells were counted
microscopically in 20 random high-powered fields (40).
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Only cells whose nuclei had completely invaded through
the membrane were counted. Each experimental condition,
including control, was performed in triplicate and the
average number of invading cells was then calculated
for all experimental conditions.
Percent invasion was determined for each cell line
under each experimental condition using the following
formula: % invasion¼ (mean number of treated cells
invading through the Matrigel/mean number of
untreated cells migrating through the Matrigel)
multiplied by a 100. The cell lines were then ranked
according to their invasive ability.
Irradiation
Before irradiation, the cells were incubated with IM as a
concentration of 10 mM. Cells were seeded at a
concentration of 500 000 cells per ml in micro-Petri dishes
and allowed to incubate overnight. The following day the
Petri dishes were exposed to graded doses of gamma
irradiation (137 Cs source/gamma cell 1000) 0, 2, 4, 6, 8,
and 10 Gy. One set of dishes per cell line with and without
IM was kept as controls without exposure to irradiation.
After irradiation, RB cells were removed from all Petri
dishes containing 500 000 cells per plate and spun down
for 5 min at 120 g. Cells were then diluted to a
concentration of 50 000 cells/ml in 5% FBS RPMI
solution. These dilutions were then seeded in a 96-well
plate format at a concentration of 10 000 cells per well
and left to incubate 37 1C for 48 h. The MTT proliferation
assay was done as described above in triplicate per
exposure condition and controls.
Immunocytochemistry
Cells from the two human Rb cell lines were diluted to a
concentration of 200 000 cells in 300mM. Cytospins were
prepared using a Cytospin3 machine (Shandon, Pittsburgh,
PA, USA). All slides were then immunostained with a
polyclonal primary antibody anti-human C-kit (A4502,
DakoCytomation, Burlington, ON, Canada); PDGFR-b
(sc-339, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA); PDGFR-a (sc-338, Santa Cruz Biotechnology,
Inc.), and c-Abl (sc-887, Santa Cruz Biotechnology, Inc.)
using the Ventana automated immunostaining machine
(Ventana Medical Systems Inc., Tucson, AZ, USA)
programmed to stain wet loaded slides. The slides were
incubated at a dilution of 1 : 30 (C-kit), 1 : 100 (PDGFR-b),
1 : 200 (PDGFR-a), and 1 : 200 (c-Abl) for 30 min at 37 1C,
followed by the application of biotinylated secondary
antibody (8 min, 37 1C), then an avidin/streptavidin
enzyme conjugate complex (8 min, 37 1C). Finally, the
antibody was detected by Fast Red chromogenic
substrate and counterstained with hematoxylin.
Western blot
Protein samples from the cell lines were prepared using
100 ml of 1 electrophoresis sample buffer (62.5 mM TRIS
pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue,
50 mM DTT) per million cells, which was then boiled for
5 min. The same number of cells per sample was used.
Twenty microliter of total protein was separated on 7.5%
SDS-PAGE gel and transferred to a polyvinylidene
difluoride membrane (Amersham Bioscience,
Piscataway, NJ, USA). The membrane was blotted for
specific antibody according to ProteoQwest Colorimetric
Western Blot Kit (Sigma-Aldrich, Oakville, ON, Canada).
The primary polyclonal antibody against C-kit (A4502,
DakoCytomation), PDGFR-b (sc-339, Santa Cruz
Biotechnology, Inc.), PDGFR-a (sc-338, Santa Cruz
Biotechnology, Inc.), and c-Abl (sc-887, Santa Cruz
Biotechnology, Inc.) were used at a dilution 1 : 1000
overnight at 4 1C. The secondary, goat anti-rabbit
peroxidase-conjugated antibody (Sigma-Aldrich,
Oakville) was used to visualize the proteins on the
membrane diluted 1 : 10 000. TMB substrate was used
to visualize the bands. A broad range molecular weight
marker (Bio-Rad, Mississauga, ON, Canada) was used
and the positive controls were used according to
specificity of the date sheet of the antibody. We used P815
lysed cell line to C-kit, 3T3/NIH cell lysate to PDGFR-a,
THP-1 cell lysate to PDGFR-b, and K562 cell lysate to
C-Abl.
Statistical analysis
The Student’s t-test was used to compare differences on
the proliferation and invasion assays. It was also used to
compare results after different doses of radiation. A value
of Po0.05 was considered statistically significant.
Results
Proliferation
The Y-79 cell line showed a higher proliferation rate than
the WERI-RB-1 Rb cell line with an average absorption of
0.172±0.006 compared with 0.048±0.002. IM caused a
statistically significant reduction in the proliferation rates
in both of them (Po0.001), although the Y-79 cell line
revealed a more significant decrease (Figure 1).
Invasion
Statistically significant reduction in the invasion rates of
the treated group was found for both cell lines. The
invasion rate of the treated cells was 27.27% of the
control for Y-79 (P¼ 0.014) and 40.74% for WERI-RB-1
(P¼ 0.029; Figure 2).
Effect of imatinib mesylate
LR de Moura et al
94
Eye
Irradiation
The effect of radiation was significantly more
pronounced in the Rb cell lines treated with IM. The
difference in the proliferation rates between treated and
non-treated cell lines was statistically significant in both
cell lines at all radiation doses (Po0.05; Figure 3).
Expression of the tyrosine kinase receptors
The two cell lines were strongly positive for c-Abl,
positive for PDGFR-a and -b but negative for C-kit on
immunocytochemistry (Figure 4) and western blot
(Figure 5).
Discussion
Developing drugs to specifically inhibit oncogenes has
been a major goal of cancer research. Identifying the
appropriate intracellular targets is critical to this process.
Some of the activated oncogenes implicated in the
pathogenesis and progression of malignancy are tyrosine
kinases.14 PTK are enzymes that transfer phosphate from
adenosine triphosphate to specific amino acids on
substrate proteins. The phosphorylation of these proteins
leads to the activation of signal-transduction pathways,
which have a critical role in a variety of biologic
processes, including cell growth, differentiation, and
death. Several PTKs are deregulated and overexpressed
in human cancers and are thus attractive targets for
selective pharmacological inhibitors.8
Bcr–Abl, the causative molecular abnormality in CML
is a prototypic oncogenic kinase. The FDA approved the
tyrosine kinase inhibitor IM, in 2001, for the treatment of
CML. It was the first time that this compound had the
approval for the treatment of a human malignancy. The
success of IM in CML led rapidly to studies in other
cancers associated with activation of two other tyrosine
kinases known to be sensitive to IM, C-kit the target of
IM in the GIST, and PDGFR the target of this compound
Figure 1 The graph shows the proliferation assay results
comparing a control (white) and the cells treated with IM
10mM (black). A statistical difference was seen for the two cell
lines (Po0.001).
Figure 2 The graph shows the Matrigel invasion assay results
for each Rb cell line before (white) and after (black) treatment
with IM 10mM. The data were presented and graphed as
percentages calculated by normalizing values obtained for the
untreated cells as 100%. A statistically significant reduction was
seen for both cell lines.
Figure 3 Graphical representation of the effect of IM and
radiation on cell lines. The absorbance level is seen in the y axis
while the doses of radiation are shown in the x axis. The
difference in the proliferation rates between treated (solid line)
and non-treated (dashed line) cell lines was statistically
significant in both cell lines at all radiation doses.
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in some solid tumors like glioma, osteosarcoma, and
neuroblastoma.14–17
In an effort to identify additional agents for the
treatment of Rb, we performed pre-clinical studies of IM
and its targets in two human Rb cell lines. In the first part
of our study, we evaluated the anti-proliferative and anti-
invasive effects of IM in Y79 and WERI-RB-1 human Rb
cell lines. Cell proliferation has been suggested by Kim
et al18 to be a significant histopathological parameter that
can predict the clinical outcome of Rb. In our study, IM
reduced the proliferation rate of both cell lines, specially
Y79, which considered the most aggressive one. Our
study also demonstrated that IM markedly reduced the
invasive ability of both cell lines. The invasion assay is
Figure 4 Immunocytochemistry of Rb cell lines. C-kit was negative for both cell lines whereas all other markers were positive.
(a) Y-79 (Bcr–Abl,  400). (b) WERI-RB-1 (Bcr–Abl,  400). (c) Y-79 (C-kit,  400). (d) WERI-RB-1 (C-kit,  400). (e) Y-79 (PDGFR-a,
 400). (f) WERI-RB-1 (PDGFR-a,  400). (g) Y-79 (PDGFR-b,  400). (h) WERI-RB-1 (PDGFR-b,  400).
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important to show the ability of cells to invade an
artificial basement membrane, reflecting the ability of
cells to migrate through the extracellular matrix get
access to the systemic circulation. The use of an artificial
basement membrane provides us the opportunity to
study if a drug can alter the invasive potential of cells by
counting the number of cells that invade a matrigel layer.
A drug that can inhibit or reduce the invasiveness ability
of a cell, would not only decrease the chances of a
malignant cell to escape the primary site of a tumor, but
also decrease the ability of circulating malignant cells to
extravasate and seed distant organs.
According to Chevez-Barrios et al19, Rb cell
lines used in this study (WERI-RB and Y79) have
very distinctive behavior as observed in a murine
animal model. When inoculated in these animals, the
Y-79 cell line generated aggressive tumors with invasive
and metastatic potential. On the other hand, the WERI-
RB cell line gave rise to localized tumors that only
invaded the anterior structures of the eye without
any sign of extraocular spread or metastasis. In the
study herein, the proliferation and invasive rate observed
in these two cell lines supported that publication,
confirming the more aggressive phenotype of the
Y-79 cell line.
The concentration of IM used for our in vitro studies
was 10 mM. This concentration is equivalent to the
highest drug concentration that has been achieved in the
blood of patients receiving 1000 mg per day of IM, the
maximum tolerated dose reported by clinical trials.20 At
that dose and schedule, the plasma concentration of IM
ranged from 6 to 10 mM. In vitro studies have been
published investigating the effect of IM in other types of
tumor cell lines. McGary et al15 investigated the potential
of IM as a therapy for osteosarcoma, the most common
primary malignant bone tumor in children. They
demonstrated that IM could inhibit PDGF-mediated
growth and led to apoptosis of osteosarcoma cells in vitro
by selective inhibition of the PDGFR tyrosine kinase.
Pereira et al9 reported a significant decrease by IM in the
proliferation and invasion rates of five different cell lines
of another intra-ocular tumor, uveal melanoma. To the
best of our knowledge, this is the first report about the
in vitro effects of IM on Rb cells.
In the second part of our study, we investigated the
ability of IM to radiosensitize Rb cells. There is increasing
amount evidence that IM may work as radiosensitizing
agent. Studies have been done to investigate the
potentiating effect of this drug on the cytotoxic effect of
ionizing radiation. Holdhoff et al21 demonstrated that IM
could enhance significantly the cytotoxic effect of the
radiation in a human glioblastoma cell line, although this
effect was not seen in human breast and colon cancer cell
lines. One of the proposed mechanisms for this effect on
the glioblastoma cell line was the decrease in the levels of
cellular tyrosine phosphorylation, and specifically the
phosphorylation of PDGFR-b. Oertel et al22 studied the
combined effect of IM and radiation in vitro and in vivo.
They showed that IM could enhance the tumor growth
reduction induced by fractioned radiotherapy in
glioblastoma and carcinoma models. In Bcr–abl-positive
cell lines IM and irradiation was also reported to be
significantly synergistic.23
Gerweck et al24 demonstrated that the intrinsic
radiosensitivity of tumor cells is a major determinant of
tumor response to radiation, and not the tumor stroma
radiosensitivity, like some other studies have suggested.
Zhang et al25 studied the effect of radiation on the Rb cell
lines Y79 and WERI-RB-1, the same cell lines of our
study. They confirmed what has been demonstrated
clinically, that Rb cells are very sensitive to radiation.
They showed that, for both Rb cell lines, radiation
resulted in a time and dose-dependent induction of
apoptosis associated with decreased viability. Apoptosis
was indeed the predominant form of cell death observed
morphologically in Rb cells following radiation.25 Kondo
et al26 also demonstrated that radiation in human Rb cell
linesY79 and WERI-RB-1-induced apoptosis. To the best
of our knowledge, this is the first time that IM has been
shown to increase the radiosensitivity of Rb cells lines.
The combination of IM and radiation is a promising
emerging therapy as it is possible that IM can selectively
enhance the radiosensitivity of the tumor, thereby
reducing the needed doses of radiation. This reduction in
radiation would hopefully lead to a reduction in
treatment-related complications and the rates of
secondary tumor development.
The mechanism underlying the synergistic effect of IM
and radiation remains unclear and is probably
multifaceted. Some authors believe that IM’s anti-
neoplastic activity in vivo could be attributed in part to its
anti-angiogenic effects, and the combination of the drug
and radiation could further reduce microvessel density.22
The inhibition of specific PTKs, specially C-kit and
PDGFR-a and -b, can synergistically increase the
radiation damage in neoplastic cells, as it is known that
Figure 5 Western blot. None of the cell lines had detectable
levels of c-kit. All other markers were positive.
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both are related to the repair of radiation-induced DNA
damage. As an example, signaling of C-kit by stem cell
factor is known to reduce radiation-induced apoptosis
and cytotoxicity, thus conferring radioprotection to
malignant cells.27
In the final part of our study, we investigated the
presence of the targets of IM in both Rb cell lines by
western blot and immunocytochemistry. The only target
that was not expressed in these cell lines was the C-kit
(CD117, stem cell factor receptor). PDGFR-a and -b were
positive while c-Abl was strongly positive. There was no
difference in expression of the IM’s targets between the
two cell lines. The results were the same for Y79 and
WERI-RB-1 cell line in western Blot and in the cytospins.
Even considering that these are preliminary studies, we
suggest that the effects of IM on Rb cells are through
PDGFR and c-Abl, and not C-kit. Further studies will
have to be completed to determine which target is the
one responsible for the effects that IM has on Rb cell
lines. The presence or absence of only one of its targets is
not enough to determine the potential effects of
IM in a clinical setting. It is also known that IM may
have others mechanisms of action other than the
inhibitory effect on the growth kinases,22 and further
studies still have to be done to determine how that
drug works in the distinctive types of tumors.
Nevertheless, our preclinical results warrant further
trials to study the effect of IM on Rb, specially in
association with radiotherapy.
Summary
What was known before
K IM works as a radiosensitizing agent for some solid
tumors.
K The effects of IM on Rb cell lines is unknown.
What this study adds
K Rb cell lines expresses bcr–abl, PDGFR but not c-kit.
K IM decreases proliferation, invasion and increases the
radiosensitivity of Rb cell lines.
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